Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS

2 Apr 2015

Abstract excerpt

Atypical hemolytic uremic syndrome (aHUS) is a genetic, life-threatening disease characterized by uncontrolled complement activation, systemic thrombotic microangiopathy (TMA), and vital organ damage. We evaluated the effect of terminal complement blockade with the anti-C5 monoclonal antibody eculizumab on biomarkers of cellular processes involved in TMA in patients with aHUS longitudinally, during up to 1 year...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Complement system in diseases
Share to Platelet Disorders and Treatments
Share to Renal Diseases and Glomerulopathies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 25833956
DOI: 10.1182/blood-2014-09-600411

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUSPMID 25833956Read ↗

Biomarkers of terminal complement activation confirm the diagnosis of aHUS and differentiate aHUS from TTPSemantic proximity Read ↗

aHUS caused by complement dysregulation: new therapies on the horizon.Semantic proximity Read ↗

Complement-mediated HUS revisited: evolving insights into pathophysiology, diagnosis, and treatment.Semantic proximity Read ↗

Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.Semantic proximity Read ↗

Consensus regarding diagnosis and management of atypical hemolytic uremic syndromeSemantic proximity Read ↗

An update for atypical haemolytic uraemic syndrome: Diagnosis and treatment. A consensus documentSemantic proximity Read ↗

A review of genetic and epigenetic biomarkers involved in the occurrence of atypical hemolytic uremic syndrome and its therapeutic strategies.Semantic proximity Read ↗

Atypical hemolytic uremic syndrome, genetic basis, and clinical manifestations.Semantic proximity Read ↗

Spectrum of Complement-Mediated Thrombotic Microangiopathies: Pathogenetic Insights Identifying Novel Treatment ApproachesSemantic proximity Read ↗

Atypical hemolytic uremic syndrome: diagnosis, management, and discontinuation of therapy.Semantic proximity Read ↗

Diseases of complement dysregulation-an overview.Semantic proximity Read ↗

Complement‐driven hemolytic uremic syndromeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.